Tirzepatide drives an average 22.5% body-weight loss in trials — but stopping the drug leads to roughly 14% regain in a year, even with diet and exercise.
From semaglutide to retatrutide and tesamorelin: the seven peptides reshaping obesity care, what trials really show, and what to ask before starting.
Tesamorelin is trending as a midlife belly-fat peptide, but the FDA approval, the 18% visceral-fat number, and the cancer warnings tell a more complicated story for women over 40.
Plateaus on GLP-1 drugs are biology, not failure. Here is an evidence-honest review of the five "stacks" people consider, including which ones have trial data.
What 90 days of semaglutide actually changes — pulled from STEP-1, STEP-4, and real-world cohorts, not marketing photos.
Retatrutide produced 28.7% mean weight loss in its first Phase 3 readout. Here's what TRIUMPH-4 actually showed and what it didn't.
GLP-1 microdosing is everywhere in 2026. Here is what the evidence actually shows about sub-therapeutic semaglutide and tirzepatide doses.
After the FDA declared the semaglutide shortage resolved in February 2025, the legal market for compounded GLP-1s narrowed sharply while a black market expanded. This guide walks through 503A vs 503B vs research peptides, the salt-form red flag, counterfeit incidents on record, and the credentialing checklist and questions that separate a legitimate compounding pharmacy from a dangerous knockoff.
AOD-9604 is sold as fat loss without hunger. The 24-week trial in 536 people that was supposed to confirm it failed in 2007. Here is what the evidence actually shows.
Research shows weighted vest walking burns more calories proportional to load and may help maintain bone density -- but only during structured exercise, not passive wear.
OTC glucose monitors, vitamin patches, and biosensor innovations are reshaping personal health tracking. Here's what works, what doesn't, and what's next.
Tirzepatide drives an average 22.5% body-weight loss in trials — but stopping the drug leads to roughly 14% regain in a year, even with diet and exercise.
The goal isn’t to be comfortable with change — it’s to be comfortable with one small change, on a schedule, held for a year.
We’re recording with NotebookLM. Expect a deep-dive and a short-form version of each issue’s best essays, delivered to your favorite podcast app when we launch.